In a significant escalation of the ongoing conflict between public companies and short sellers, Lunai Bioworks (Nasdaq: LNAI) has filed a lawsuit naming ten defendants in a coordinated naked short selling fraud scheme. The suit is notable not just for its allegations of market manipulation, but for its invocation of the federal racketeering statute (RICO), seeking treble damages for what the company describes as a systemic attempt to destroy its market value.
The 80% Failure to Deliver Threshold
According to the complaint, Lunai’s forensic investigation identified 'failures to deliver' (FTDs) equal to more than 80% of its total outstanding shares. In the mechanics of the stock market, an FTD occurs when a seller does not deliver the securities they have sold within the standard settlement period. While occasional FTDs can occur due to administrative errors, a sustained level of 80% suggests the practice of 'naked' shorting—selling shares that have not been borrowed or even located.
Lunai claims that single-day trading volumes frequently reached multiples of the entire share count, a statistical anomaly that the company argues is impossible without the injection of 'phantom' shares into the market. By flooding the market with these non-existent shares, the defendants allegedly suppressed the stock price, creating a self-fulfilling prophecy of decline.
RICO as a Corporate Weapon
The decision to file under the Racketeer Influenced and Corrupt Organizations (RICO) Act represents a high-stakes legal strategy. Originally designed to combat organized crime, RICO allows for triple damages if a plaintiff can prove a pattern of racketeering activity. By framing naked short selling as a 'scheme' involving multiple participants—potentially including broker-dealers and hedge funds—Lunai is attempting to bypass the standard hurdles of securities litigation.
This case follows a growing trend of issuers taking a proactive, forensic approach to short campaigns. Lunai has stated that its review is ongoing and that it is monitoring current trading in real-time. This 'active defense' model suggests that companies are no longer willing to wait for regulatory intervention, which often comes years after the damage is done.
The Forensic Trail
The success of Lunai’s suit will likely hinge on its ability to link the FTD data to specific defendants. Naked shorting is notoriously difficult to prove because the 'plumbing' of the stock market—the clearing and settlement process—is largely opaque to individual issuers. However, by utilizing forensic analysts to map trading volumes against known short positions and settlement failures, Lunai aims to provide a definitive trail of manipulation. If successful, this case could provide a blueprint for other small-cap companies targeted by aggressive short campaigns.
Key Takeaways
- Extreme FTDs: The claim of 80% failures to deliver is an extraordinary figure that, if proven, indicates systemic market failure.
- RICO Strategy: The use of racketeering laws allows for treble damages, significantly increasing the financial risk for defendants.
- Real-Time Monitoring: Lunai’s use of real-time forensic analysis marks a shift in how companies defend against short sellers.
- Small-Cap Vulnerability: The case highlights the specific risks faced by biotech and tech companies where volatility is high and liquidity can be easily manipulated.
Sources
- Finviz / LNAI Press Release — Details on the lawsuit and the 80% failure to deliver allegations, June 2026.
Original reporting by Finviz. This article is desk analysis prepared by The Forensic Ledger from publicly available sources, summarized with citation to the original.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.
